HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Parker, C. J. Search for Related Content PubMed PubMed Citation Articles by Parker, C. J.

Molecular Basis of Paroxysmal Nocturnal Hemoglobinuria

Department of Medicine, Division of Hematology/Oncology, University of Utah School of Medicine and the Veterans Affairs Medical Center, Salt Lake City, Utah, USA

Key Words. Paroxysmal nocturnal hemoglobinuria • Anemia • Hemolytic • Glycosyl phosphatidylinositols • Hematopoiesis • Hematopoietic stem cell • CD55 • CD59 • PIG-A • X chromosome

Correspondence: Dr. Charles J. Parker, Hematology/Oncology Section (111c), VA Medical Center, 500 Foothill Boulevard, Salt Lake City, UT 84148, USA.

The purpose of this review is to summarize recent studies that have led to a more complete understanding of the molecular basis of paroxysmal nocturnal hemoglobinuria (PNH). Somatic mutations of PIG-A arising in pluripotent hematopoietic stem cells are necessary for the development of PNH. PIG-A is an X-linked gene that is essential for synthesis of the glycosyl phosphatidylinositol (GPI) moiety that serves as a membrane anchor for a functionally diverse group of cell surface proteins. Consequently, the progeny of stem cells with mutant PIG-A are deficient in all GPI-anchored proteins (GPI-AP). Among the GPI-AP that are expressed on hematopoietic cells are two important regulators of the complement system, decay-accelerating factor, (CD55) and membrane inhibitor of reactive lysis, (CD59). It is the deficiency of erythrocyte CD55 and CD59 that accounts for the intravascular hemolysis and hemoglobinuria that are the clinical hallmarks of PNH. A remarkable feature of PNH is that the peripheral blood is a mosaic composed of variable proportions of GPI-AP⁺ and GPI-AP^– cells and that, in an individual patient, the GPI-AP^– cells can be derived from multiple mutant stem cells. Currently, however, there is no evidence that the PIG-A mutation per se provides a proliferative advantage. Thus, PNH is not a monoclonal disease with a malignant phenotype. Rather, the mutant stem cells appear to dominate hematopoiesis because under some pathological conditions, GPI-AP deficiency is advantageous. The close association of PNH with aplastic anemia suggests that the selection pressure arises as a consequence of a specific type of bone marrow injury.

This article has been cited by other articles:

				A. Hill, S. H. Ridley, D. Esser, R. G. Oldroyd, M. J. Cullen, P. Kareclas, S. Gallagher, G. P. Smith, S. J. Richards, J. White, et al. Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy Blood, March 1, 2006; 107(5): 2131 - 2137. [Abstract] [Full Text] [PDF]

				D. S. Holt, M. Botto, A. E. Bygrave, S. M. Hanna, M. J. Walport, and B. P. Morgan Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria Blood, July 15, 2001; 98(2): 442 - 449. [Abstract] [Full Text] [PDF]

				Y. Murakami, T. Kinoshita, Y. Maeda, T. Nakano, H. Kosaka, and J. Takeda Different Roles of Glycosylphosphatidylinositol in Various Hematopoietic Cells as Revealed by a Mouse Model of Paroxysmal Nocturnal Hemoglobinuria Blood, November 1, 1999; 94(9): 2963 - 2970. [Abstract] [Full Text] [PDF]